Skip to main content
. 2017 Dec 21;9(2):2646–2659. doi: 10.18632/oncotarget.23522

Figure 3. E-cadherin facilitate epithelial differentiation.

Figure 3

(A and B) Representative image of ADSC morphology under the microscope after ADSCs given LV5-E-cadherin or LV3-shE-cadherin (×200). (C and D) Western blot analyses of protein levels of E-cadherin, CK18 and ZO-1 after ADSCs treatment with LV5-E-cadherin or LV3-shE-cadherin. β-actin was used as an internal control. (E and F) qRT-PCR analyses of mRNA levels of E-cadherin, CK18 and ZO-1 after ADSCs given LV5-E-cadherin or LV3-shE-cadherin. (G and H) Immunofluorescence analysis of the expression of E-cadherin, CK18 and ZO-1 after ADSCs given LV5-E-cadherin or LV3-shE-cadherin (×100). Nuclei are visualized by 4,6-diamidino-2-phenylindole staining. These data are expressed as the mean ± SD (**P<0.01). Each experiment was repeated at least three times.